Spirocyclic CGRP Receptor Antagonists for Migraine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders involving CGRP, such as migraine and cluster headache, are limited in efficacy and specificity, with existing CGRP antagonists having limitations in receptor binding and functional antagonism.
Innovation Solution
Development of novel compounds of the formula I, which act as antagonists of CGRP receptors, specifically designed to bind and inhibit CGRP receptor activity, thereby providing therapeutic benefits for conditions associated with CGRP involvement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CGRP antagonists are used, then some therapeutic effect is achieved, but receptor binding specificity and functional antagonism are limited
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters including the substituent R1 at position 8, the spirocyclic core structure, and the substituent R2 at position 9 to optimize receptor binding specificity. These controlled modifications to molecular parameters enable improved CGRP receptor antagonism while maintaining manageable structural complexity
Solution Approach 2:
The compounds represent composite molecular structures combining a spirocyclic core with specific aromatic or heteroaromatic substituents (R1 and R2 groups). This composite architecture integrates multiple functional elements that work synergistically to achieve high receptor binding specificity and potent CGRP antagonism
2Reliability
If current CGRP treatments are used, then some symptom relief is provided, but efficacy is limited
Solution Approach 1:
The patent achieves improved therapeutic efficacy through parameter changes in the molecular structure, specifically optimizing the spirocyclic core and substituent groups to enhance CGRP receptor binding affinity and functional antagonism, thereby providing superior symptom relief compared to existing treatments
3Reliability
If novel compounds with improved CGRP receptor binding are developed, then therapeutic benefits are enhanced, but molecular structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (R1 and R2 substituents) at localized positions (positions 8 and 9) on the spirocyclic core. These localized modifications enhance functional antagonism at the CGRP receptor binding site without requiring complex changes throughout the entire molecular structure
Solution Approach 2:
The molecular structure is segmented into distinct functional modules: a spirocyclic core structure and separate substituent groups (R1 and R2). This segmentation allows independent optimization of each module's contribution to receptor binding, achieving enhanced functional antagonism through modular design rather than monolithic complexity
Data Source
AI summary
Compounds of formula I: I (wherein variables A1, A2, A3, A4, M, N, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.